Exicure Q2 net loss widens, exploring strategic alternatives

Reuters

Aug 09

Exicure <a href="https://laohu8.com/S/QTWO">Q2</a> net loss widens, exploring strategic alternatives

Overview

Exicure Q2 net loss widens to $2.6 mln from $0.6 mln yr ago
Company's cash position declines to $7.9 mln from $12.5 mln end of 2024
Exicure needs substantial financing to continue operations, per management

Outlook

Company needs substantial financing to continue operations
Exicure exploring strategic alternatives
Exicure uncertain about obtaining additional financing

Result Drivers

ACQUISITION IMPACT - Increased R&D and G&A expenses due to acquisition of GPCR Therapeutics USA Inc.
CASH DECLINE - Cash position fell to $7.9 mln from $12.5 mln at end of 2024
FINANCIAL NEEDS - Management states substantial financing needed to continue operations

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Net Income Before Tax		-$2.62 mln
Q2 Net Income		-$2.62 mln
Q2 Operating Expenses		$2.51 mln
Q2 Operating Income		-$2.51 mln

Press Release: ID:nBwbwQ1MGa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2558574789"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558574789\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558574789?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-09 04:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558574789","market":"fut","top_or_hot":-1,"title":"Exicure Q2 net loss widens, exploring strategic alternatives","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Exicure <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens, exploring strategic alternatives</title></head><body><p><span>Overview</span></p><ul><li><p>Exicure Q2 net loss widens to $2.6 mln from $0.6 mln yr ago</p></li><li><p>Company's cash position declines to $7.9 mln from $12.5 mln end of 2024</p></li><li><p>Exicure needs substantial financing to continue operations, per management</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company needs substantial financing to continue operations</p></li><li><p>Exicure exploring strategic alternatives</p></li><li><p>Exicure uncertain about obtaining additional financing</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ACQUISITION IMPACT - Increased R&amp;D and G&amp;A expenses due to acquisition of GPCR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> USA Inc.</p></li><li><p>CASH DECLINE - Cash position fell to $7.9 mln from $12.5 mln at end of 2024</p></li><li><p>FINANCIAL NEEDS - Management states substantial financing needed to continue operations</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income Before Tax</p></td><td></td><td><p>-$2.62 mln</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$2.62 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$2.51 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Income</p></td><td></td><td><p>-$2.51 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBwbwQ1MGa</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exicure Q2 net loss widens, exploring strategic alternatives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExicure Q2 net loss widens, exploring strategic alternatives\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-09 04:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Exicure <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens, exploring strategic alternatives</title></head><body><p><span>Overview</span></p><ul><li><p>Exicure Q2 net loss widens to $2.6 mln from $0.6 mln yr ago</p></li><li><p>Company's cash position declines to $7.9 mln from $12.5 mln end of 2024</p></li><li><p>Exicure needs substantial financing to continue operations, per management</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company needs substantial financing to continue operations</p></li><li><p>Exicure exploring strategic alternatives</p></li><li><p>Exicure uncertain about obtaining additional financing</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ACQUISITION IMPACT - Increased R&amp;D and G&amp;A expenses due to acquisition of GPCR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> USA Inc.</p></li><li><p>CASH DECLINE - Cash position fell to $7.9 mln from $12.5 mln at end of 2024</p></li><li><p>FINANCIAL NEEDS - Management states substantial financing needed to continue operations</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income Before Tax</p></td><td></td><td><p>-$2.62 mln</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$2.62 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$2.51 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Income</p></td><td></td><td><p>-$2.51 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBwbwQ1MGa</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XCUR","symbol_name":"Exicure, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nPLX503A5B:1","article_id":"2558574789","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558574789","pubTimestamp":1754683905,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Exicure Q2 net loss widens, exploring strategic alternativesOverviewExicure Q2 net loss widens to $2.6 mln from $0.6 mln yr agoCompany's cash position declines to $7.9 mln from $12.5 mln end of 2024Ex","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XCUR":"Exicure, Inc.","BK4139":"生物科技"},"translate_title":"Exicure第二季度净亏损扩大，探索战略替代方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XCUR":0.9},"content_text":"Exicure Q2 net loss widens, exploring strategic alternativesOverviewExicure Q2 net loss widens to $2.6 mln from $0.6 mln yr agoCompany's cash position declines to $7.9 mln from $12.5 mln end of 2024Exicure needs substantial financing to continue operations, per managementOutlookCompany needs substantial financing to continue operationsExicure exploring strategic alternativesExicure uncertain about obtaining additional financingResult DriversACQUISITION IMPACT - Increased R&D and G&A expenses due to acquisition of GPCR Therapeutics USA Inc.CASH DECLINE - Cash position fell to $7.9 mln from $12.5 mln at end of 2024FINANCIAL NEEDS - Management states substantial financing needed to continue operationsKey DetailsMetricBeat/MissActualConsensus EstimateQ2 Net Income Before Tax-$2.62 mlnQ2 Net Income-$2.62 mlnQ2 Operating Expenses$2.51 mlnQ2 Operating Income-$2.51 mlnPress Release: ID:nBwbwQ1MGa(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}